Researchers at The Scripps Research Institute and the IAVI Neutralizing Antibody Center are developing a novel experimental vaccine targeting the germline to stimulate precursor B cells and produce broadly neutralizing antibodies (bnAbs) against the membrane-proximal external region (MPER) of the gp41 protein found in the HIV-1 envelope.
Monte Rosa Therapeutics Inc. has submitted an IND application to the FDA for MRT-6160, a highly selective and orally bioavailable molecular glue degrader directed against VAV1 in development for systemic and neurological autoimmune diseases.
Signal transducer and activator of transcription 3 (STAT3) plays a key role in cell proliferation observed in colorectal cancer (CRC), where up-regulation of STAT3 accelerates tumorigenesis and promotes metastasis.
Resolution Therapeutics Ltd. has received approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a phase I/II study of its lead candidate RTX-001 in patients with decompensated liver cirrhosis.
Oncopeptides AB has selected its first candidate drug based on the company’s unique platform for small polypeptide-based innate killer engagers (SPiKE). The SPiKE platform uses multispecific constructs, able to bind to multiple targets simultaneously.
There is growing evidence of the role of soluble endoglin in the biology of platelets, including thrombosis. French researchers have investigated the role of genetic variants in the gene encoding endoglin, ENG, and the risk of venous thrombosis development.
Senescence is a hallmark of aging, and senescent cells have a reputation to match. They are ‘zombie cells,’ sort of dead themselves but alive enough to poison their surroundings through senescence-associated secretory phenotype (SASP). The reality, though, is more complex.
New single-step genome editing techniques that enable the insertion, inversion or deletion of long DNA sequences at specified genome positions have been demonstrated in bacteria. The advance opens the door to the development of programmable methods for rearranging DNA, using recombinase enzymes guided by RNA. The two different approaches to using insertion sequences (IS) – some of the simplest and most compact mobile genetic elements – are described in two papers published in Nature and Nature Communications.